Therapeutic area intelligence for CD123-targeted therapy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

AstraZeneca →

Assets

AZD9829 →

Recent signals(1)

ClinicalJuly 5, 2026

AstraZeneca initiates Phase I/II trial of AZD9829 for CD123+ hematological malignancies

AstraZeneca is conducting Phase I/II trial to evaluate AZD9829 in patients with CD123+ hematological malignancies.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.